CLINICAL AND SUBCLINICAL CHARACTERISTICS OF BREAST CANCER PATIENTS UNDERGOING TRASTUZUMAB TREATMENT
Main Article Content
Abstract
Objective: Describing the clinical and subclinical characteristics of the breast cancer
patient treated with Trastuzumab at Thong Nhat hospital.
Subjects and methods: A retrospective study on 48 patients with breast cancer were
treated with Trastuzumab at Thong Nhat hospital.
Results: Mean age: 48.4 ± 3.4 years old. The 45-60 age group accounted for the
largest proportion with 47.92%. Functional symptoms: the proportion of patients who
self-examined the tumor accounted for the highest rate with 64.58%. There were
12.50% of patients with pain symptoms, 10.42% of patients with nipple discharge.
Physical symptoms: tumor in the upper-external quadrant accounted for the largest
percentage with 58.33%. The average size of the tumors was 2.78 ± 1.32 (cm). The
main type of lesions was detected on ultrasound was local lesion with over 77.08%
with an unknown boundary feature (66.67%) and invasive, accounting for 43.75%.
Histopathological type accounted for the highest proportion was the invasive tubular
carcinoma (79.92%). Histological degree accounted for the highest percentage was
degree 2 with 45.83%. Stage II accounted for the highest rate with 39.58%, stage VI
had the lowest rate with 10.42%.
Conclusion: Common age of breast cancer patients was 45 - 60 years old, mainly
the self-examined tumor, common breast tumors were found in the upper-external
quadrant. On ultrasound, mainly the local lesion, the boundary was not clear. The
histopathological type was the invasive tubular carcinoma.
Article Details
Keywords
Breast cancer, trastuzumab, clinical and subclinical features.
References
Soerjomataram et al., Global Cancer
Statistics 2018: GLOBOCAN Estimates
of Incidence and Mortality Worldwide
for 36 Cancers in 185 Countries. Ca
Cancer J Clin, 2018; 68: 394–424.
[2] Bui Dieu et al., Trends in breast cancer
in Vietnam to 2020. Vietnam Medical
Journal, 2012; 393(1): 127-131.
[3] Fredholm H, Eaker S, Frisell J et al.,
Breast cancer in young women: poor
survival despite intensive treatment. PloS
One, 2009; 4(11): e7695.
[4] Phung Thi Huyen, Evaluation of results of
adjuvant chemotherapy regimens 4AC +
4T combined with trastuzumab on patients
with breast cancer stage II, III with Her 2
neu positive, Doctor of Medicine thesis,
Hanoi Medical University, 2016.
[5] Le Hong Quang, Application of imaging
techniques and biopsy of portal nodes in
assessing axillary lymph node metastasis
in breast cancer patients, Doctor of
Medicine Thesis, Hanoi Medical
University, 2012.
[6] Khouri MG, Douglas PS, Mackey JR et al.,
Cancer therapyinduced cardiac toxicity
in early breast cancer: Addressing the
unresolved issues. Circulation research,
2012; 126: 2749–2763.
[7] Somaira Nowsheen, Aziz K, Park JY et
al., Trastuzumab in Female Breast Cancer
Patients With Reduced Left Ventricular
Ejection Fraction. J Am Heart Assoc,
2018; Aug 7;7(15):e008637
[8] Veronesi U, Viale G, Paganelli G et al.,
Sentinel lymph node biopsy in breast
cancer: ten-year results of a randomized
controlled study. Ann Surg, 2010; 251:
595-600.
[9] Nguyen Van Thang, Study on the
diagnostic value of mammogram x-ray
combined with ultrasound of the breast.
Journal of Practical Medicine, 2013;
4:22-29.